MALVERN, Pa., Oct. 17, 2024 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene and cell therapies, biologics, and vaccines, today announced that it will host a conference call and live webcast to discuss the Company's third quarter 2024 financial results and provide a business update at 8:30 a.m. ET on Friday, November 8, 2024. Ocugen will issue a pre-market earnings announcement on the same day. ...

文章核心观点 - 美国FDA已经解除了对Ocugen公司研发的OCU200治疗糖尿病黄斑水肿(DME)的临床试验的临床保留 [1] - OCU200是一种重组融合蛋白,由肿瘤抑素和转铁蛋白组成,可能有潜力治疗DME患者,包括对目前抗VEGF疗法无反应的患者 [2] - Ocugen公司计划进一步探索OCU200治疗糖尿病视网膜病变和湿性年龄相关性黄斑变性的潜力,这两种疾病合计影响近900万美国人 [4] 关键要点总结 1. OCU200的研发进展 - Ocugen公司的OCU200获得FDA解除临床试验临床保留,即将开始I期临床试验 [1] - OCU200是一种重组融合蛋白,由肿瘤抑素和转铁蛋白组成,可能有潜力治疗DME患者,包括对目前抗VEGF疗法无反应的患者 [2] - OCU200的独特特性可能使其能够治疗DME的血管并发症,肿瘤抑素是其活性成分,可与整合素受体结合,而转铁蛋白有助于将肿瘤抑素靶向递送到视网膜和脉络膜 [2] 2. DME的现状及市场潜力 - DME是糖尿病患者中最常见的威胁视力的疾病,会导致视力模糊和逐步视力丧失 [3] - 目前美国约有74.6万人患有DME [3] - Ocugen公司还计划探索OCU200治疗糖尿病视网膜病变和湿性年龄相关性黄斑变性的潜力,这两种疾病合计影响近900万美国人 [4]

MALVERN, Pa., Oct. 02, 2024 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene and cell therapies, and vaccines, today announced that Dr. Shankar Musunuri, Chairman, Chief Executive Officer, and Co-founder of Ocugen will present at the 2024 Cell & Gene Meeting on the Mesa being held October 7-9, 2024 at the Arizona Biltmore in Phoenix, AZ. "The Cell & Gene Meeting on the Mesa convenes industry de ...

MALVERN, Pa., Sept. 24, 2024 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene and cell therapies, and vaccines, today announced that Dr. Arun Upadhyay, Chief Scientific Officer, Head of Research & Development, will participate in an in-person fireside chat moderated by Daniil Gataulin, PhD, Senior Biotech Research Analyst, at Chardan's 8th Annual Genetic Medicines Conference being held Septembe ...

Jonathan Storey Source: Corporate Presentation. August 2024. Ocugen Inc. (NASDAQ:OCGN) is a clinical-stage biotechnology company developing gene and cell therapies using its proprietary platforms. They aim to restore retinal function in various ocular diseases. Since I last covered OCGN, the company has made promising strides targeting conditions such as retinitis pigmentosa [RP], goographic atrophy related to dry age-related macular degeneration [dAMD], Stargardt disease, and wet AMD. It also has an intrig ...

文章核心观点 - 公司专注于发现、开发和商业化创新基因和细胞疗法以及疫苗,致力于改善患者健康并为全球患者带来希望[1][2] - 公司正在加强与美国和印度之间的生物技术合作,在印度海得拉巴设立了新的研发基地[1] - 公司首席执行官将参加一个关于美印生物技术合作的论坛,探讨合作的机遇和挑战[1][2] 公司概况 - 公司专注于发现、开发和商业化创新基因和细胞疗法以及疫苗[1][2] - 公司致力于改善患者健康并为全球患者带来希望[1][2] - 公司正在加强与美国和印度之间的生物技术合作,在印度海得拉巴设立了新的研发基地[1] 行业动态 - 公司首席执行官将参加一个关于美印生物技术合作的论坛,探讨合作的机遇和挑战[1][2] - 该论坛由美国国家科学院和印度国家科学院联合举办,旨在识别美印生物技术合作的短期、中期和长期机遇[1] - 论坛将发布同行评审的研讨会论文集[1]

MALVERN, Pa., Sept. 03, 2024 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene and cell therapies, and vaccines, today announced that Dr. Shankar Musunuri, Chairman, Chief Executive Officer and Co-Founder of Ocugen will participate in a fireside chat at the H.C. Wainwright 26th Annual Global Investment Conference taking place from September 9-11, 2024 in New York, NY. "The H.C. Wainwright Global ...

MALVERN, Pa., Aug. 28, 2024 (GLOBE NEWSWIRE) -- Ocugen, Inc. ("Ocugen" or the "Company") (NASDAQ: OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene and cell therapies and vaccines, today announced that dosing is complete in the third cohort of its Phase 1/2 GARDian clinical trial for OCU410ST (AAV-hRORA)—a modifier gene therapy candidate being developed for Stargardt disease. Stargardt disease affects approximately 100,000 people in the United States (U.S.) an ...

Ocugen, Inc. (OCGN) announced that Health Canada has provided it a No Objection Letter to initiate the phase III liMeliGhT study evaluating its modifier gene therapy product candidate, OCU400, for treating retinitis pigmentosa (RP). Shares of OCGN were up 4.6% on Aug. 26 following the announcement of the news. Ocugen has already received clearance from the FDA to initiate a phase III study on OCU400 for the treatment of RP, a rare genetic disorder that can lead to vision loss and blindness. The FDA had prev ...

MALVERN, Pa., Aug. 26, 2024 (GLOBE NEWSWIRE) -- Ocugen, Inc. ("Ocugen" or the "Company") (NASDAQ: OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene and cell therapies and vaccines, today announced that Health Canada provided a "No Objection Letter" to initiate the OCU400 Phase 3 liMeliGhT (pronounced "limelight") clinical trial in Canada. OCU400 is a modifier gene therapy product candidate being developed for retinitis pigmentosa (RP). "Expanding the clinical ...